Anti-Human CCR7 Reference Antibody (CAP-100, RUO) (HB053026)

Name: Anti-Human CCR7 Reference Antibody (CAP-100, RUO)
Brand: abinScience
SKU: HB053026
Price: 176 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HB053026
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG
ID de clone	CAP-100
Activité biologique	CAP-100 (0.1-10 ng/uL) demonstrates the most potent binding to CCR7 immunogen SYM1899 (100 ng) with a EC 50 of 1.78 ng/mL [1]. CAP-100 (0.01-100 ug/mL) shows dose-dependent inhibition of ligand-induced activation, reaching maximal inhibitions close to 100% in CCR7 + CHO-K1 cells stimulated with CCL19 [1]. CAP-100 (0.1-100 ug/mL) binds to CCR7 + non-tumor PB or BM cells from healthy donors at high experimental concentrations [1]. CAP-100 (1-100 ug/mL) impairs the increase of D-actin upon CCL19/CCL21 stimulation in CLL cells [1]. CAP-100 (0.1-100 ug/mL, 4 h) demonstrates a strong dose-related inhibitory activity against CCR7-driven T-PLL cells migration towards 1 ug/mL of CCL19 or CCL21 [1]. CAP-100 (10 ug/mL) impairs CCR7-induced migration of CCL cells in trans-endothelial migration (TEM) assays [1]. CAP-100 (10-100 ug/mL, 24 h) does not mediate direct specific-induced cell death but impairs the viability of CCR7-mediated cells which is the protective function in CLL [1]. CAP-100 (10 ug/mL) activated human NK-92-CD16 + cells to induce a strong ADCC on target CLL cells [1]. CAP-100 (10 ug/mL, i.v., one single dose) reduces in vivo homing of CCR7-expressing cells to lymph node of NSG mice [1]. CAP-100 (25-200 ug/mouse, i.v., one single dose) shows prolonged median overall survival regardless of dose and reduces tumor burden as well as reducing lymph node infiltration in Granta-519-luc + -bearing mice [1]. CAP-100 (10-200 ug/mouse, i.v., one single dose) significantly extends the lifespan of JVM-3-bearing SCID mice compared to Trastuzumab () (200 ug) [1].
Système d'expression	Mammalian cells
Cible	CDw197, EVI1, CMKBR7, CCR7, C-C CKR-7, CD197, CCR-7, Epstein-Barr virus-induced G-protein coupled receptor 1, MIP-3 beta receptor, EBI1, CC-CKR-7, BLR2, EBV-induced G-protein coupled receptor 1, C-C chemokine receptor type 7
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P32248
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	CAP-100, CAP100, CAP100
Contexte	C-C chemokine receptor type 7 (CD197/CCR7) is a ~42 kDa protein. Receptor for the MIP-3-beta chemokine. Probable mediator of EBV effects on B-lymphocytes or of normal lymphocyte functions.
Reférences	1. Cuesta-Mateos C, et al., Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL. MAbs. 2021 Jan-Dec;13(1):1917484. [HB053026]
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 (LALAPG) Recombinant Isotype Control Antibody (HyHEL-10) (HP688307) Human IgG1 (LALA) Recombinant Isotype Control Antibody (HyHEL-10) (HP688107)

Images

Bioactivity

SEC-HPLC detection for Research Grade Anti-Human CD197/CCR7 (CAP-100).
SDS-PAGE

SDS-PAGE for Research Grade Anti-Human CD197/CCR7 (CAP-100).